CINGW - Cingulate to Attend DCAT Week 2024 in New York City | Benzinga
KANSAS CITY, Kan., March 06, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, announced today that it will be attending DCAT Week (Drug, Chemical & Associated Technologies Association) March 18-21, 2024, in Midtown Manhattan.
Cingulate Chairman and CEO Shane J. Schaffer, and Cingulate COO Laurie A. Myers, will be joined at the DCAT by Global PharmaPartners, INC. (also known worldwide as "GPP") to host meetings regarding Cingulate's pipeline and product portfolio, including its lead Phase 3 candidate CTx-1301 (dexmethylphenidate) for the treatment of attention deficit/hyperactivity disorder (ADHD), and CTx-2103 (buspirone) for the treatment of anxiety.
"Cingulate is excited to be attending DCAT this year with Global PharmaPartners, Inc. to seek out business partnerships with excellent co-development/commercial parties, and we believe it's an excellent venue to discuss our leading assets, pipeline, and disruptive drug delivery platform technology," Schaffer said.
What: DCAT Week 2024
Where: Omni Berkshire Place Hotel: 21 E 52nd St Madison Ave, New York City, NY 10022-5389
When: March 18-21, 2024
Contact: To arrange meetings with Cingulate leadership please contact Jonathan Camerer with Global PharmaPartners (GPP):
417-576-5082
jonathancamerer@globalpharmapartners.com
About Attention Deficit/Hyperactivity Disorder (ADHD)
ADHD is a chronic neurobiological and developmental disorder that affects millions of children and often continues into adulthood. The condition is marked by an ongoing pattern of inattention and/or hyperactivity-impulsivity that interferes with functioning or development. In the U.S., approximately 6.4 million children and adolescents (11 percent) aged under the age of 18 have been diagnosed with ADHD. Among this group, approximately 80 percent receive treatment, with 65-90 percent demonstrating clinical ADHD symptoms that persist into adulthood. Adult ADHD prevalence is estimated at approximately 11 million patients (4.4 percent), almost double the size of the child and adolescent segment combined. However, only an estimated 20 percent receive treatment.
About CTx-1301
Cingulate's lead candidate, CTx-1301, utilizes Cingulate's proprietary PTR drug delivery platform to create a breakthrough, multi-core formulation of the active pharmaceutical ingredient dexmethylphenidate, a compound approved by the FDA for the treatment of ADHD. Dexmethylphenidate is part of the stimulant ...